Marinomed updates financial calendar and participates in upcoming industry and investor conferences
- Q3/2021 financial results to be published on 22 November 2021 (previous date: 24 November 2021)
- Marinomed to attend Deutsches Eigenkapitalforum 2021 and to hold a presentation on 22 November at 11:30 am
- Marinomed to attend CPhI from Nov 9-11, 2021 to introduce new technology partnership offering “Solv4U”
Korneuburg, Austria, 28 October 2021 – Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today that it will take part in the German Equity Forum (Deutsches Eigenkapitalforum, EKF) organized by the Deutsche Börse. The conference, which will take place on 22-24 November, connects international companies from different industries with investors and analysts.
Marinomed will also publish their Q3 financial results on 22 November; the earnings call will take place from 10 am to 11 am before the presentation at EKF. Pascal Schmidt, Chief Financial Officer of Marinomed, and Stephanie Kniep, Investor Relations, will be available for discussions in 1on1 meetings all three days of the conference.
Deutsches Eigenkapitalforum (EKF) Online
22-24 November 2021
Speakers: Dr. Andreas Grassauer, Chief Executive Officer, and Pascal Schmidt, Chief Financial Officer
Monday, 22 November 2021, 11:30 am-12:00 pm – Virtual Room: Oslo
More information as well as a detailed schedule are available on the conference website.
Further, Marinomed will attend CPhI, an industry conference providing a global platform to suppliers, manufacturers and buyers in the pharmaceutical industry:
CPhI worldwide(R) 2021
9-11 November 2021 – Fiera Milano, Milan, Italy
25 October – 19 November 2021, Online Conference & Networking
Marinomed will be on site to inform about Solv4U, Marinomed’s partnering service based on the Marinosolv(R) technology. The company’s exhibition stand #3F71 is located on the ICSE General Floor. Marinomed will also be glad to receive virtual partnering requests via CPhI-online.
Marinosolv(R) is an innovative technology platform that enables the solubilization and enhances the bioavailability of small molecules and peptides that are hardly soluble in aqueous formulations. Consequently, new treatments of a multitude of diseases can be envisaged. The use of the Marinosolv(R) technology can facilitate efficient drug delivery with a low systemic off-target activity. Existing drugs and off-patent active ingredients can be improved and re-patented as part of new formulations using Marinosolv(R). Marinomed provides Marinosolv(R) formulation development in technology partnerships for active ingredients at all stages of drug discovery and lifecycle extension. For more information on Marinosolv(R), please visit https://www.marinosolv.com/en. Scientific publications on Marinosolv(R) can be accessed at https://www.marinosolv.com/en/publications.
About Marinomed Biotech AG
Marinomed Biotech AG (Korneuburg, Austria) (VSE:MARI) is an Austrian science-based biotech company with globally marketed therapeutics. The company is listed on the Prime Market of the Vienna Stock Exchange. Marinomed focuses on the development of innovative products based on two patent-protected technology platforms. The Marinosolv(R) technology increases the solubility and bioavailability of compounds that are hardly soluble in aqueous formulations. The Carragelose(R) platform comprises innovative patent-protected products targeting viral infections of the respiratory tract and may also reduce the risk of an infection with SARS-CoV-2. Carragelose(R) is used as a virus blocker in nasal sprays, throat sprays, and lozenges, which are sold via international partners in over 40 countries. Marinomed, Marinosolv(R) and Carragelose(R) are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only. Further information is available at https://www.marinomed.com.
For further inquiries contact:
This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise.
28.10.2021 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de